skip to the content
Publications

Flu references

A list of references included in Influenza World is provided below. To view the abstract via PubMed, simply select the link to the right of the citation.

  1. Adams PF, Marano MA. Current estimates from the National Health Interview Survey, 1994. Vital Health Stat 10 1995: 1–260. [Abstract]
  2. Aoki FY, Macleod MD, Paggiaro P, et al. Early administration of oral oseltamivir increases the benefits of influenza treatment. J Antimicrob Chemother 2003; 51: 123–9. [Abstract]
  3. Arden NH. The epidemiology of influenza in children. Pediatr Ann 2000; 29:
    678–82. [Abstract]
  4. Banning M. Influenza: incidence, symptoms and treatment. Br J Nurs 2005; 14: 1192–7. [Abstract]
  5. Bright RA, Medina MJ, Xu X, et al. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet 2005; 366: 1175–81. [Abstract]
  6. Cannell JJ, Vieth R, Umhau JC, et al. Epidemic influenza and vitamin D. Epidemiol Infect 2006; 134: 1129–40. [Abstract]
  7. Carrat F, Tachet A, Housset B, Valleron AJ, Rouzioux C. Influenza and influenza-like illness in general practice: drawing lessons for surveillance from a pilot study in Paris, France. Br J Gen Pract 1997; 47: 217–20. [Abstract]
  8. Center for Disease Control and Prevention. CDC recommends against the use of amantadine and rimantadine for the treatment or prophylaxis of influenza in the United States during the 2005–06 influenza season.
  9. Center for Infectious Disease Research & Policy. 2006 Summit Coverage: Conference poll: 18% of businesses have a pandemic plan. February 15, 2006.
  10. Centers for Disease Control and Prevention. Epidemiology and Prevention of Vaccine-Preventable Diseases (The Pink Book). Atkinson W, Hamborsky J, McIntyre L, Wolfe S, eds. 10th ed. Washington DC: Public Health Foundation, 2007.
  11. Centers for Disease Control and Prevention: Key facts about influenza and influenza vaccine, 2006.
  12. Centres for Disease Control and Prevention. Key facts about avian influenza (bird flu) and avian influenza A (H5N1) virus.
  13. Congressional Budget Office. A potential influenza pandemic: possible macroeconomic effects and policy issues. December 2005.
  14. Corey L, Rubin RJ, Bregman D, Gregg MB. Diagnostic criteria for influenza B-associated Reye's syndrome: clinical vs. pathologic criteria. Pediatrics 1977; 60:
    702–8. [Abstract]
  15. Couch RB. Advances in influenza virus vaccine research. Ann NY Acad Sci 1993; 685: 803–12. [Abstract]
  16. de Jong JC, Beyer WEP, Palache AM, et al. Mismatch between the 1997/1998 influenza vaccine and the major epidemic A (H3N2) virus strain as the cause of an inadequate vaccine-induced antibody response to this strain in the elderly. J Med Virol 2000; 61: 94–9. [Abstract]
  17. Deloitte Center for Health Solutions. Business preparations for pandemic flu. 2006.
  18. Eccles R. Understanding the symptoms of the common cold and influenza. Lancet Infect Dis 2005; 5: 718–25. [Abstract]
  19. Esposito S, Marchisio P, Bosis S, et al. Clinical and economic impact of influenza vaccination on healthy children aged 2–5 years. Vaccine 2006; 24: 629–35. [Abstract]
  20. Financial Times. HSBC warns on possible bird flu toll. [press release]. January 10, 2006.
  21. Fleming DM, Ayres JG. Diagnosis and patterns of incidence of influenza, influenza-like illness and the common cold in general practice. J R Coll Gen Pract 1988; 38: 159–62. [Abstract]
  22. Fleming DM. Influenza diagnosis and treatment: a view from clinical practice. Philos Trans R Soc Lond B Biol Sci 2001; 356: 1933–43. [Abstract]
  23. Ghendon Y. Influenza – its impact and control. World Health Stat Q 1992 (2–3): 306–11.  [Abstract]
  24. Glasgow JF. Reye's syndrome: the case for a causal link with aspirin. Drug Saf 2006; 29: 1111–21. [Abstract]
  25. Glezen WP, Payne AA, Snyder DN, Downs TD. Mortality and influenza. J Infect Dis 1982; 146: 313–21. [Abstract]
  26. Glezen WP, Taber LH, Frank AL, Gruber WC, Piedra PA. Influenza virus infections in infants. Pediatr Infect Dis J 1997; 16: 1065–8. [Abstract]
  27. Govaert TME, Thijs CT, Masurel N, et al. The efficacy of influenza vaccination in elderly individuals. A randomised double blind placebo-controlled trial. JAMA 1994; 272:1661–5. [Abstract]
  28. Govorkova EA, Ilyushina NA, Boltz DA, et al. Efficacy of oseltamivir therapy in ferrets inoculated with different clades of H5N1 influenza virus. Antimicrob Agents Chemother 2007; 51: 1414–24. [Abstract]
  29. Hak E, Hoes AW, Verheij TJM. Influenza vaccinations: who needs them and when? Drugs 2002; 62: 2413–20. [Abstract]
  30. Hayden FG, Atmar RL, Schilling M, et al. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N Engl J Med 1999; 341: 1336–43. [Abstract]
  31. Hayden FG, Belshe R, Villanueva C, et al. Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis. J Infect Dis 2004; 189: 440–9. [Abstract]
  32. Hulisz D. Symptomatic treatment of the common cold and influenza. Pharmacy Times, October 2001.
  33. Hurt AC, Selleck P, Komadina N, et al. Susceptibility of highly pathogenic A (H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes. Antiviral Res 2007; 73: 228–31. [Abstract]
  34. Jackson HC, Roberts N, Wang M, et al. Management of influenza: use of new antivirals and resistance in perspective. Clin Drug Invest 2000; 20(6): 447–54. [Abstract]
  35. Jefferson T, Deeks JJ, Demicheli V, et al. Amantidine and rimantadine for preventing and treating influenza A in adults. Cochrane Database Syst Rev 2006: CD001169. [Abstract]
  36. Jefferson T, Rivetti D, Rivetti A, et al. Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review. Lancet 2005; 366: 1165–74. [Abstract]
  37. Kaiser L, Wat C, Mills T, et al. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med 2003; 163: 1667–72. [Abstract]
  38. Kamps BS, Hoffmann C, Preiser W, eds. Influenza report.
  39. Kavet J. A perspective on the significance of pandemic influenza. Am J Public Health 1977; 67: 1063–70. [Abstract]
  40. Keech M, Scott AJ, Ryan PJ. The impact of influenza and influenza-like illness on productivity and healthcare resource utilization in a working population. Occup Med (Lond) 1998; 48: 85–90. [Abstract]
  41. Khater F, Moorman JP. Complications of influenza. South Med J 2003; 96: 740–3. [Abstract]
  42. KNTV-TV (NBC). Bay area companies prepare for bird flu. [press release]. February 14, 2006.
  43. Kurowski M, Oo C, Wiltshire H, Barrett J. Oseltamivir distributes to influenza virus replication sites in the middle ear and sinuses. Clin Drug Invest 2004; 24: 49–53.
  44. Laver WG, Bischofberger N, Webster RG. Disarming flu viruses. Sci Am 1999; 280: 78–87. [Abstract]
  45. Lew W, Chen X, Kim CU. Discovery and development of GS 4104 (oseltamivir): an orally active influenza neuraminidase inhibitor. Curr Med Chem 2000; 7: 663–72. [Abstract]
  46. Li KS, Guan Y, Wang J, et al. Genesis of a highly pathogenic and potentially pandemic H5N1 influenza virus in eastern Asia. Nature 2004; 430: 209–13. [Abstract]
  47. Loughlin J, Poulios N, Napalkov P, et al. A study of influenza and influenza-related complications among children in a large US health insurance plan database. Pharmacoeconomics 2003; 21: 273–83. [Abstract]
  48. Loughlin JE, Alfredson TD, Ajene AN, et al. Risk for respiratory events in a cohort of patients receiving inhaled zanamivir: A retrospective study. Clin Ther 2002; 24: 1786–99. [Abstract]
  49. Maciosek MV, Solberg LI, Coffield AB, Edwards NM, Goodman MJ. Influenza vaccination health impact and cost effectiveness among adults aged 50 to 64 and 65 and older. Am J Prev Med 2006; 31: 72–9. [Abstract]
  50. Matsuzaki Y, Katsushima N, Nagai Y, et al. Clinical features of influenza C virus infection in children. J Infect Dis 2006; 193: 1229–35. [Abstract]
  51. Meier CR, Napalkov PN, Wegmuller Y, Jefferson T, Jick H. Population-based study on incidence, risk factors, clinical complications and drug utilisation associated with influenza in the United Kingdom. Eur J Clin Microbiol Infect Dis 2000; 19: 834–42. [Abstract]
  52. Monto AS, Sullivan KM. Acute respiratory illness in the community. Frequency of illness and the agents involved. Epidemiol Infect 1993; 110: 145–60. [Abstract]
  53. Moorman JP. Viral characteristics of influenza. South Med J 2003; 96: 758–61. [Abstract]
  54. Moscona A. Neuraminidase inhibitors for influenza. N Engl J Med 2005; 353: 1363–73. [Abstract]
  55. Munoz FM. The impact of influenza in children. Semin Pediatr Infect Dis 2002; 13: 72–8. [Abstract]
  56. Neuzil KM, Mellen BG, Wright PF, Mitchel EF, Jr., Griffin MR. The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children. N Engl J Med 2000; 342: 225–31. [Abstract]
  57. Nguyen-Van-Tam J. Epidemiology of influenza. In: Nicholson K, Webster RG, Hay A, eds. Textbook of influenza. Oxford, UK: Blackwell Science, 1998: 181–206. [No link available]
  58. Nichol KL. Efficacy/clinical effectiveness of inactivated influenza virus vaccines in adults. In: Nicholson KG, Webster RG, Hay AJ, eds. Textbook of influenza. Oxford, UK: Blackwell Science, 1998: 358–72.
  59. Nicholson K. Human influenza. In: Nicholson K, Webster RG, Hay A, eds. Textbook of influenza. Oxford, UK: Blackwell Science, 1998: 219–64.
  60. Nicholson KG, Aoki FY, Osterhaus AD, et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet 2000; 355: 1845–50. [Abstract]
  61. Oner AF, Bay A, Arslan S, et al. Avian influenza A (H5N1) infection in eastern Turkey in 2006. N Engl J Med 2006; 355: 2179–85. [Abstract]
  62. Osterholm MT. Preparing for the next pandemic. N Engl J Med 2005; 352: 1839–42. [Abstract]
  63. Oxford J. Oseltamivir in the management of influenza. Expert Opin Pharmacother 2005; 6: 2493–500. [Abstract]
  64. Oxford JS, Lambkin R. Targeting influenza virus neuraminidase – a new strategy for antiviral therapy. Drug Discovery Today 1998; 3: 448–56.
  65. Pan American Health Organization. Avian vs. pandemic flu: understanding the threat (press release).
  66. Patriarca PA, Arden NH, Koplan JP, Goodman RA. Prevention and control of type A influenza infections in nursing homes. Benefits and costs of four approaches using vaccination and amantadine. Ann Intern Med 1987; 107: 732–40. [Abstract]
  67. Patriarca PA, Strikas RA. Influenza vaccine for healthy adults? N Engl J Med 1995; 333: 933–4. [Abstract]
  68. Peltola V, Reunanen T, Ziegler T, Silvennoinen H, Heikkinen T. Accuracy of clinical diagnosis of influenza in outpatient children. Clin Infect Dis 2005; 41: 1198–200. [Abstract]
  69. Perrie Y. Influenza: treatment and prevention. Pharm J 2006; 277: 399–402.
  70. Poehling KA, Edwards KM, Weinberg GA, et al. The under-recognized burden of influenza in young children. N Engl J Med 2006; 355: 31–40. [Abstract]
  71. Roberts NA, Wiltshire HR, Mendel DB, et al. Oseltamivir carboxylate is effective against all subtypes of influenza neuraminidase [Abstract]. ASM Biodefence Research Meeting, 9–12 March 2003, Baltimore, MD, USA. 
  72. Roche Products Pty Limited. Tamiflu approved product information, 2005.[Link to Tamiflu prescribing information]
  73. Ruigrok R. Structure of influenza A, B and C viruses. In: Nicholson K, Webster RG, Hay A, eds. Textbook of influenza. Oxford, UK: Blackwell Science, 1998:
    29–42.
  74. Ruiz G. Business continuity plans for an avian flu pandemic largely off workforce radar. Workforce Management. December 12, 2005.
  75. Ryan J, Zoellner Y, Gradl B, Palache B, Medema J. Establishing the health and economic impact of influenza vaccination within the European Union 25 countries. Vaccine 2006; 24: 6812–22. [Abstract]
  76. Salleras L, Dominguez A, Pumarola T, et al. Effectiveness of virosomal subunit influenza vaccine in preventing influenza-related illnesses and its social and economic consequences in children aged 3–14 years: a prospective cohort study. Vaccine 2006; 24: 6638–42. [Abstract]
  77. Sato M, Hosoya M, Kato K, Suzuki H. Viral shedding in children with influenza virus infections treated with neuraminidase inhibitors. Pediatr Infect Dis J 2005; 24: 931–2. [Abstract]
  78. Shorman M, Moorman JP. Clinical manifestations and diagnosis of influenza. South Med J 2003; 96: 737–9. [Abstract]
  79. Stephenson I, Nicholson KG. Influenza: vaccination and treatment. Eur Respir J 2001; 17: 1282–93. [Abstract]
  80. Szucs T. The socio-economic burden of influenza. J Antimicrob Chemother 1999; 44 Suppl B: 11–5. [Abstract]
  81. Taber LH, Paredes A, Glezen WP, Couch RB. Infection with influenza A/Victoria virus in Houston families, 1976. J Hyg (Lond) 1981; 86: 303–13. [Abstract]
  82. Tacken M, Braspenning J, Spreeuwenberg P, et al. Patient characteristics determine differences in the influenza vaccination rate more so than practice features. Prev Med 2002; 35: 401–6. [Abstract]
  83. Treanor J. Influenza vaccine – outmaneuvering antigenic shift and drift. N Engl J Med 2004; 350: 218–20. [Abstract]
  84. Treanor JJ, Campbell JD, Zangwill KM, et al. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 2006; 354: 1343–51. [Abstract]
  85. Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA 2000; 283: 1016–24. [Abstract]
  86. US Dept. of Health and Human Services Centers for Disease Control and Prevention: Is it a cold or the flu? 
  87. Ward P, Small I, Smith J, Suter P, Dutkowski R. Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic. J Antimicrob Chemother 2005; 55(Suppl 1): i5–i21. [Abstract]
  88. Welliver R, Monto AS, Carewicz O, et al. Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. JAMA 2001; 285: 748–54. [Abstract]
  89. Whitley RJ, Hayden FG, Reisinger KS, et al. Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J 2001; 20: 127–33. [Abstract]
  90. World Bank. Evaluating the economic consequences of avian influenza.
  91. World Health Organization. Antivirals – their use and availability.
  92. World Health Organization. Avian influenza frequently asked questions.
  93. World Health Organization. Consultation on priority public health interventions 
  94. World Health Organization. Cumulative number of confirmed human cases of avian influenza A (H5N1) reported to WHO.
  95. World Health Organization. Current WHO phase of pandemic alert.
  96. World Health Organization. Estimating the impact of the next influenza pandemic: enhancing preparedness.
  97. World Health Organization. Influenza fact sheet, no. 211, March 2003.
  98. World Health Organization. Influenza vaccines. Weekly Epidemiological Record 2000; 35: 281–8.
  99. World Health Organization. Report on global surveillance of epidemic-prone infectious diseases. 2000: 89–93.
  100. World Health Organization. Summary of the second WHO consultation on clinical aspects of human infection with avian influenza A (H5N1) virus.
  101. World Health Organization. Ten things you need to know about pandemic influenza.
  102. World Health Organization. WHO checklist for influenza preparedness planning.
  103. World Health Organization. WHO global influenza preparedness plan.
  104. World Health Organization. WHO rapid advice guidelines on pharmacological management of humans infected with avian influenza A (H5N1) virus.
  105. World Health Organization. WHO recommendations on the use of rapid testing for influenza diagnosis, 2005.
  106. World Health Organization: WHO interim guidelines on clinical management of humans infected by influenza A (H5N1).
  107. Yen HL, Monto AS, Webster RG, et al. Virulence may determine the necessary duration and dosage of oseltamivir treatment for highly pathogenic A/Vietnam/1203/04 influenza virus in mice. J Infect Dis 2005; 192: 665–72. [Abstract]
  108. Zambon M. Laboratory diagnosis of influenza. In: Nicholson K, Webster RG, Hay A, eds. Textbook of influenza. Oxford, UK: Blackwell Science, 1998: 291–313.
  • "I would describe flu as something that makes you feel very, very ill. You get a headache, aching bones, and are generally fed up"
  • "When I get flu symptoms I feel like a train has run over me"
  • "I felt very sick and, during the first week, I had high temperature. Flu was very different to a cold. I went back to work after two and a half weeks. Then I suffered a setback for another week"
  • "I run a guesthouse; flu would be a real pest for me. I couldn’t cook, I shouldn’t cook, and I wouldn’t cook, so I would need to get a lot of extra help in. It would cost me a lot more money. So flu’s a real problem, a right downturn"
  • "I work on my own and when I can’t work, I have to try not to infect my little children, so they avoid getting the flu as well"
  • "I feel a little numb, like I’m in another dimension. Because in general I have sore throat, headache, I feel all clogged-up. Usually a sensation like I’m floating in the air"
  • "Shivers, sweats, makes you ache. Last time I had flu I was off for two weeks"
  • "I think that I would probably be concerned that I would pass flu onto my children, who might not be able to deal with it as well as I would"
  • "Flu makes you feel like you’ve been hit over the head with a baseball bat. You don’t feel like you can get yourself out of bed as all your energy is drawn from you"
  • "I was incapable of working. It just wasn’t possible at all… and my flu dragged on for more than a week"
  • "I have no strength. It annoys me because I can do nothing, it seems like I’m wasting my time"
  • "Flu’s like being hit by a truck because you feel completely gone. There is no energy left in your body. You are suffering from high temperature. You’re sweating a lot and you feel really unwell"
  • "First of all infinite tiredness, then I feel like sleeping and don’t want to eat"
  • "I felt really miserable because my muscles and my bones were aching. Well, I can hardly describe it, I just felt really awful, absolutely miserable"
  • "It’s like there’s something huge treading on your head, like a deafening noise that destroys the eardrums"
  • "The fever was constantly rising – I immediately measured my temperature as soon as I got home. It was 41°C and it kept rising and I was wondering what’s going on. I was really scared! Everything was hurting and it all happened so fast. Flu came out of the blue"
  • "I always feel like my limbs have iron weights tied to them and I’m going to fall over any minute, a really stuffy runny nose and feel antisocial"
  • "I was totally dependent on others! I was incapable of doing anything at all"
  • "The real flu knocks you for six – you just don’t want to move or do anything. It’s not very nice"
  • "Not being able to go to work. Not being able to do the things I have to do at home and the commitments that I have day by day"